Abstract

There is unequivocal acceptance of the variety of enormous potential liquid nucleic acid- based diagnostics seems to offer. However, the existing controversies and the increased awareness of RNA-based techniques in society during the current global COVID-19 pandemic have made the readiness of liquid nucleic acid-based diagnostics for routine use a matter of concern. In this regard - and in the context of oncology - our review presented and discussed the status quo of RNA-based liquid diagnostics. We summarized the technical background of the available assays and benchmarked their applicability against each other. Herein, we compared the technology readiness level in the clinical context, economic aspects, implementation as part of routine point-of-care testing as well as performance power. Since the preventive care market is the most promising application sector, we also investigated whether the developments predominantly occur in the context of early disease detection or surveillance of therapy success. In addition, we provided a careful view on the current biotechnology investment activities in this sector to indicate the most attractive strategies for future economic success. Taken together, our review shall serve as a current reference, at the interplay of technology, clinical use and economic potential, to guide the interested readers in this rapid developing sector of precision medicine.

Keywords

tekoča biopsija;proste nukleinske kisline v obtoku;eksosom;liquid biopsy;circulating free nucleic acids;exosome;

Data

Language: English
Year of publishing:
Typology: 1.02 - Review Article
Organization: UL MF - Faculty of Medicine
UDC: 616-006
COBISS: 80452099 Link will open in a new window
ISSN: 2072-6694
Views: 103
Downloads: 39
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: tekoča biopsija;proste nukleinske kisline v obtoku;eksosom;
Type (COBISS): Article
Pages: str. 1-26
Volume: ǂVol. ǂ13
Issue: ǂno. ǂ20
Chronology: 2021
DOI: 10.3390/cancers13205060
ID: 15098192